Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort

Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohortPharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated <i>NRG3</i> rs1649942 and <i>BRE</i> rs7572644 variants in an independent cohort, Published online: 05 October 2018; doi:10.1038/s41397-018-0056-yPharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort

Source: The Pharmacogenomics Journal - October 5, 2018 Category: Drugs & Pharmacology Authors: Ricardo Pinto Joana Assis Augusto Nogueira Carina Pereira Sara Coelho Mariana Brand ão Jo ão Dias Sara Alves Deolinda Pereira Rui Medeiros Source Type: research